Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

May 31, 2013

Study Completion Date

October 31, 2014

Conditions
Drug Resistant Malaria Due to Plasmodium Falciparum
Interventions
DRUG

Arthemeter-lumefantrine

Randomization codes were computer-generated by an offsite investigator and provided to a study nurse responsible for treatment allocation. All other study personnel were blinded to the treatment assignments, and patients were not informed of their treatment regimen. Participants from Group 1: AL, Group 2 : DHAP, Group3 : ASMQ were also given appointment card for days 1, 2, 3, 7, 14, 21, 28, 35 and 42 for clinical examination and blood smears. Blood was taken on filter paper on each of these visits.

DRUG

Artesunate mefloquine

Artequin® is an antimalarial drug presented as infant co-formulation of two separate drugs

DRUG

Dihydroartemisinin piperaquine

Malacur®. is an antimalarial drug presentad as co-formulation of two separate drugs

DRUG

Paracetamol

Paracetamol, is an antipyretic drug, presented as tablets or syrup in infants formulation

DRUG

Amoxicillin

Amoxicillin is an antibiotic with no reported activity on plasmodium

DRUG

Quinine

quinine sulphate is an antimalaria drug administered as a second line or rescue drug

Trial Locations (1)

237

CDC Hospital, Tiko

All Listed Sponsors
collaborator

Ministry of Science and Technology of the People´s Republic of China

OTHER_GOV

collaborator

National Institute for Parasitic Disease, Chinese Center for Disease Control and Prevention

UNKNOWN

lead

University of Bamenda

OTHER

NCT02974348 - Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa | Biotech Hunter | Biotech Hunter